Ohta S, Misawa A, Kyi-Tha-Thu C, Matsumoto N, Hirose Y, Kawakami Y. Melanoma antigens recognized by T cells and their use for immunotherapy. Exp Dermatol. 32(3):297-305, 2023
Yamamoto Y, Shimada S, Akiyama Y, et al, RTP4 silencing provokes tumor-intrinsic resistance to immune checkpoint blockade in colorectal cancer, Journal of Gastroenterology 58: 540-553, 2023
2022年
Katoh Y, Yaguchi T, Kubo A, et al, Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. J Immunother Cancer. 10(7): e004616, 2022
Mlecnik B, Lugli A , Bindea G, et al, Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer, Cancers (Basel). 15(2):418, 2022
Mlecnik B, Torigoe T, Bindea G, et al, Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study. Cancers (Basel). 14(18):4346, 2022
Nakagami Y, Hazama S, Suzuki N, et al, CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule. BMC Cancer. 22(1):1071, 2022
Morimoto Y, Tokumitsu A, Sone T, et al, TPT1 supports proliferation of neural stem/progenitor cells and brain tumor initiating cells regulated by Macrophage migration Inhibitory Factor (MIF). Neurochem. Res. 47(9) 2741-2756, 2022
2021年
Nakajima TE, Kadowaki S, Minashi K, et al, Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer Clin Cancer Res. 27(4):1029-1036, 2021
Hirai I, Funakoshi T, Kamijuku H, Fukuda K, Mori M, Sakurai M, Koda Y, Kato J, Mori T, Watanabe N, Noji S, Yaguchi T, Iwata T, Ohta S, Fujita T, Tanosaki R, Handa M, Okamoto S, Amagai M, Kawakami Y. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors. Cancer Sci. 112(8):3163-3172, 2021
Kinoshita T, Sayem MA, Yaguchi T, et al, Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors. Cancer Sci. 112(4):1390-1401, 2021
Fukuda K, Okamura K, Riding RL, et al, AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. J Exp Med. 218(9):e20200962, 2021
2020年
Mlecnik B, Bifulco C, Bindea G, et al, Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. J Clin Oncol. 38(31):3638-3651, 2020
Kawakami Y, Ohta S, Sayem MA, et al, Immune-resistant mechanisms in cancer immunotherapy. Int J Clin Oncol, 25(5),810-817, 2020
Kinoshita T, Kawakami Y. Interface of cancer stem cells and cancer immunity. Ann Transl Med, 8(13),810, 2020
Ohno A, Iwata T, Katoh Y, et al, Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy, Gynecol Oncol. 159(2), 329-334, 2020
Kato D, Yaguchi T, Iwata T, et al, GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. Elife. 9:e49392, 2020
Hayakawa T, Yaguchi T, Kawakami Y. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3, Cancer Sci. 111(12),4326-4355, 2020
2019年
Tanoue T, Morita S, Plichta DR, et al, A defined consortium of human gut commensals induces CD8 T cells and modulates host microbial and cancer immunity. Nature, 565:600, 2019
Tamura R, Fujioka M, Morimoto Y, et al, A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun. 0(1):5758, 2019
Osawa Y, Kojika E, Nishikawa K, et al, Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. Oncotarget. 10(32):3013-3026, 2019
2018年以前
Pagès F, Mlecnik B, Marliot F, et al, International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, 391:2128, 2018
Hanazawa A, Ito R, Katano I, Kawai K, et al. Generation of human immunosuppressive myeloid cell populations in human interleukin-6 transgenic NOG mice. Frontiers in Immunology. 2018, 9:152
Nakamura K, Yaguchi T, Ohmura G, et al. Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. Cancer Sci. 109(1):54-64, 2018
Yaguchi T, Kobayashi A, Inozume T, et al. Human PBMC transferred murine MHC class I/II deficient NOG mice enable long-term evaluation of human immune responses. Cell Mol Immunol. 14:1, 2017
Kinoshita T, Kudo-Saito C, Muramatsu R, et al. Determination of poor prognostic immune features of tumor microenvironment in nonsmoking patients with lung adenocarcinoma. Eur J Cancer. 86:15-27,2017
Kinoshita T, Muramatsu R, Fujita T, et al. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Ann Oncol. 27:2117, 2016
Inozume T, Yaguchi T, Furuta J, et al. Melanoma cells control anti-melanoma CTL Responses via interaction between TIGIT and CD155 in the effector phase. J Invest Dermatol. 136(1):255-63, 2016
Katano I, Takahashi T, Ito R, et al. Predominant Development of Mature and Functional Human NK Cells in a Novel Human IL-2-Producing Transgenic NOG Mouse. J Immunol.194(7):3513-25,2015
Nishio H, Yaguchi T, Sugiyama J, et al, Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. Br J Cancer. 110(12):2965-74,2014
Kudo-Saito C, Yura M, Yamamoto R, et al, Induction of immunoregulatory CD271+ cells by metastatic tumor cells that express human endogenous retrovirus H. Cancer Res. 74(5):1361-70,2014
Yaguchi T, Goto Y, Kido K, et al, Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol, 189:2110,2012
Iwata-Kajihara T, Sumimoto H, Kawamura N, et al. Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors. J Immunol. 187:27, 2011
Ueda R, Ohkusu-Tsukada K, Fusaki N, et al. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer. 126:919,2010
Kudo-Saito C, Shirako H, Takeuchi T, et al. Cancer metastasis is accelerated through immunosuppression during EMT of cancer cell. Cancer Cell, 16:195, 2009
Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocytes' Fcγ receptor balance toward inhibitory Fc γ RIIB in immune thrombocytopenic purpura. J Clin Invest. 118: 2939, 2008
Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF-MAPK signaling pathway is essential for cancer immune evasion in human melanoma cells. J Exp Med, 203:1651,2006
Udagawa M, Kudo-Saito C, Hasegawa G, et al. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin Cell Wall Skeleton Stimulation. Clin Cancer Res. 12(24):7465-7475,2006
Kuwana M, Matsuura E, Kobayashi K, et al. Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 105:1552,2005
Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet. 364:603,2004
Sumimoto H, Miyagishi M, Miyoshi H, et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 23: 6031,2004
Ishikawa T, Fujita T, Suzuki Y, et al. Tumor-specific Immunological Recognition of Frameshift-mutated Peptides in Colon Cancer with Microsatellite Instability. Cancer Res. 63:5564, 2003
Toda M, Iizuka Y, Kawase T, et al. Immuno-Viral Therapy of Brain Tumors by Combination of Viral Therapy with Cancer Vaccination Using a Replication-Conditional HSV. Cancer Gene Ther.9:356, 2002
Rosenberg SA, Yang J, Schwartzentruber D, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med, 4:321, 1998
Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J Immunol. 157:2539,1996
Robbins PF, El-Gamil M, Li YF, et al. A mutated b-catenin gene encodes a melanoma - specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 183:1185, 1996.
Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. PNAS, 91:6458, 1994.
Kawakami Y, Eliyahu S, Delgado CH, et al, Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. PNAS, 91:3515, 1994
